Search research articles
Contact Us
Filters
Showing results (21-30 of 129) with videos related to
Page
of 13
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
April 5, 2022
Changes in thumb tapping rates and central motor conduction times are associated in persons with multiple sclerosis
Philipp Gulde, Mehmet Cetin, Joachim Hermsdörfer, et al.
RNA (New York, N.Y.)
|
January 8, 2003
UM 9(5)h and UM 9(5)p, human and porcine noncoding transcripts with preferential expression in the cerebellum
Uwe Michel, Boris Kallmann, Peter Rieckmann, et al.
Journal of Neuroimmunology
|
November 30, 2002
CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis
Mathias Mäurer, Anke Ponath, Niels Kruse, et al.
Scientific Reports
|
August 25, 2021
State and trait of finger tapping performance in multiple sclerosis
Philipp Gulde, Heike Vojta, Joachim Hermsdörfer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 3, 2012
Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada
Jameelah Saeedi, Peter Rieckmann, Irene Yee, et al.
Neurology
|
June 16, 2010
New perspectives in the natural history of multiple sclerosis
Helen Tremlett, Yinshan Zhao, Peter Rieckmann, et al.
Neurology
|
December 10, 2009
The natural history of primary progressive multiple sclerosis
Marcus Koch, Elaine Kingwell, Peter Rieckmann, et al.
Journal of Vascular Research
|
December 15, 2006
Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells
Mathias Buttmann, Friederike Berberich-Siebelt, Edgar Serfling, et al.
Journal of Neurology
|
August 27, 2002
sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot study
Peter Flachenecker, Stefan Jung, Peter Rieckmann, et al.
Journal of Neuroimmunology
|
September 22, 2007
TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response
Mathias Buttmann, Cornelia Merzyn, Harald H Hofstetter, et al.
Page
of 13
Search research articles
Search
Showing results (21-30 of 129) with videos related to
Sort By:
Page
of 13
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
April 5, 2022
Changes in thumb tapping rates and central motor conduction times are associated in persons with multiple sclerosis
Philipp Gulde, Mehmet Cetin, Joachim Hermsdörfer, et al.
RNA (New York, N.Y.)
|
January 8, 2003
UM 9(5)h and UM 9(5)p, human and porcine noncoding transcripts with preferential expression in the cerebellum
Uwe Michel, Boris Kallmann, Peter Rieckmann, et al.
Journal of Neuroimmunology
|
November 30, 2002
CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis
Mathias Mäurer, Anke Ponath, Niels Kruse, et al.
Scientific Reports
|
August 25, 2021
State and trait of finger tapping performance in multiple sclerosis
Philipp Gulde, Heike Vojta, Joachim Hermsdörfer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 3, 2012
Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada
Jameelah Saeedi, Peter Rieckmann, Irene Yee, et al.
Neurology
|
June 16, 2010
New perspectives in the natural history of multiple sclerosis
Helen Tremlett, Yinshan Zhao, Peter Rieckmann, et al.
Neurology
|
December 10, 2009
The natural history of primary progressive multiple sclerosis
Marcus Koch, Elaine Kingwell, Peter Rieckmann, et al.
Journal of Vascular Research
|
December 15, 2006
Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells
Mathias Buttmann, Friederike Berberich-Siebelt, Edgar Serfling, et al.
Journal of Neurology
|
August 27, 2002
sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot study
Peter Flachenecker, Stefan Jung, Peter Rieckmann, et al.
Journal of Neuroimmunology
|
September 22, 2007
TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response
Mathias Buttmann, Cornelia Merzyn, Harald H Hofstetter, et al.
Page
of 13